HDBuzz-Aggregator

A small study based in Ireland asked a simple question: what does caring for someone with Huntington’s disease feel like? The answers point to isolation, stigma, and major gaps in healthcare support for many of the respondents.Read more

⏱️ 7 min read | A wrist sensor tracked arm movements in people with HD for a week and could see who had HD and who didn’t. This kind of technology could change how we measure drug effects in trials.Read more

⏱️ 9 min read | March brought us the annual CHDI therapeutics conference along with updates from 3 ongoing clinical trials. We also covered new research on somatic expansion and honored the community that built our science during Gratitude Day.Read more

A new study looking into combined music and physical therapy shows that simple rhythmic cues work better than complex music or instructions, helping to improve movement control and reducing chorea.Read more

⏱️ 6 min read | Today, on Gratitude Day, we share a guest piece from HD researcher Roy Maimon that Huntington's disease is neuroscience's best investment, not just for its scientific clarity, but for the remarkable community built around it.Read more

⏱️ 9 min read | This Gratitude Day, March 23rd, we celebrate the extraordinary partnership between HD families, scientists, and caregivers, and reflect on the place that built the science on which we all stand.Read more

⏱️ 10 min read | In a human cellular system, scientists dialed back mismatch repair genes to reduce CAG expansion by up to 69%. This work is in its early days, but it shows promise for "anti-expansion" therapies that could be used to delay HD onset.Read more

⏱️ 29 min read | Day 3 of the HD Therapeutics Conference dives into breakthrough science, new tools and bold ideas that are pushing HD research toward better treatments.Read more

⏱️ 18 min read | HDBuzz is back with Day 2 of the 21st annual CHDI HD Therapeutics Conference in Palm Springs, CA. We heard about new techniques to zoom in on HD biology in extraordinary detail.Read more

⏱️ 33 min read | HDBuzz is at CHDI's Huntington's Disease Therapeutics Conference, ready to bring you live updates from the most recent research in the field. Get ready for some exciting science!Read more

⏱️ 8 min read | An oral Huntington's disease drug is eligible for accelerated approval in Australia. This isn't full approval yet, but it opens a faster path to potentially getting this once-daily pill to people with HD sooner.Read more

The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.Read more

⏱️ 6 min read | Vico Therapeutics' Huntington’s disease drug VO659 is now being tested just twice a year, and the FDA has cleared the way for US trials to begin later this year.Read more

⏱️ 8 min read | February 2026 HD research recap: published trial data from branaplam trial; new insights into the genetics of the HD "grey zone"; plus worms, brain circuits, eye tracking, and the hidden psychological weight of living at risk.Read more

A new review from the University of Cambridge explores ocular biomarkers in HD, including retinal scans and eye movement tracking.Read more

⏱️ 8 min read | Your brain is an advanced supercomputer. But in HD, a core processor starts to malfunction. A research group at UCLA has taken a close look to visualize the specific circuits going haywire – and how they look different in HD.Read more

⏱️ 7 min read | Living at risk for Huntington’s disease imposes a massive psychological burden. A small interview-style study of at risk 12 people dove into how these people cope day-to-day.Read more

⏱️10 min read | Results from the VIBRANT-HD trial are now published in a peer reviewed journal. This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial.Read more

Two individuals with the same CAG repeat count can have vastly different HD journeys. A new study looking at individuals with 36-42 repeats shows that DNA sequence patterns play a major role in symptom onset and progression.Read more

⏱️ 7 min read | A team of researchers developed a simple platform to test how toxic different types of HTT protein clumps are using a laboratory worm model. They showed that certain types of clumps are harmful to the worms, while others are not.Read more

⏱️ 9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical FDA meeting for AMT-130, plus new insights on sleep, vaccines, and symptom management. Read the full roundup!Read more

Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data is an encouraging step as larger trials continue.Read more

⏱️5 min read |The Huntington’s disease community's unprecedented mobilization helped secure a high-priority FDA meeting to discuss the path forward for AMT-130.Read more

⏱️6 min read | Most people with HD report sleep problems, & new research suggests sleep quality is linked to many aspects of living with the disease. Wearables tracked people with HD for a year & revealed better sleep & strength training might help.Read more

⏱️6 min read | Ever wonder when to expect the next update from a clinical trial for Huntington’s disease? The HDBuzz Trial Tracker puts future updates for HD trials on a clear timeline, with deeper explanations in our articles when you want them.Read more

A recent article in the scientific journal, Nature describes “A natural experiment on the effect of herpes zoster (shingles) vaccination on dementia”. This study makes similar conclusions to other studies worldwide, and was based on a regulatory phenomenon in Wales, UK, in which depending on a precise birth date in 1933,...Read more

UniQure announced on January 9, 2026 that they have scheduled a Type A meeting with the FDA to discuss the approval pathway for AMT-130 in the United States. Type A meetings are urgent, high-priority discussions reserved for urgent issues, and they happen fast, typically within 30 days. The meeting...Read more

Doctors have been prescribing drugs to help manage Huntington’s disease (HD) symptoms like chorea (involuntary movements) and irritability for decades. But surprisingly, there are not many studies directly comparing these medications head-to-head. A new study called Neuro-HD, published in Parkinsonism & Related Disorders, helps to fill this gap. Researchers compared...Read more

As of January 1, HDBuzz is officially out on its own! Cue your celebratory party poppers as we enter this new chapter with an excited (and nervous!) smile. After lots of preparation, planning, and behind-the-scenes work, HDBuzz has become an independent nonprofit organisation. This marks a major milestone for our...Read more